

Novo Nordisk Invest 3 A/S

c/o Novo Nordisk A/S
Novo Allé
2880 Bagsværd
Denmark

CVR number 33 76 12 01

Annual Report 2018

**The Annual Report has been presented and adopted at the Annual
General Meeting on 14 May 2019.**



Chairman of the meeting

Novo Nordisk Invest 3 A/S
Contents

	<u>Page</u>
Management statement and Auditor's report	
Statement by the Board of Directors and Executive Management	3
Independent Auditor's report	4
Management Report	
Company information	6
Management Review	7
Financial Statements 1 January – 31 December 2018	
Income statement	8
Balance sheet	9
Statement of changes in equity	10
Accounting policies	11
Notes	12

Statement by the Board of Directors and Executive Management

Today, the Board of Directors and Executive Management have approved the Annual Report of Novo Nordisk Invest 3 A/S for the year 2018.

The Annual Report has been prepared in accordance with the Danish Financial Statements Act.

In our opinion, the Financial Statements give a true and fair view of the financial position of the company at 31 December 2018 and of the results of the company's operations for 2018 in accordance with the Danish Financial Statements Act.

Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position.

We recommend that the Annual Report be adopted at the Annual General Meeting.

Bagsværd, 14 May 2019

Executive Management:



Peter Bøggild

Board of Directors:



Karsten Munk Knudsen
Chairman



Lene Bang



Tomas Haagen

Novo Nordisk Invest 3 A/S

Independent Auditor's report

To the Shareholder of Novo Nordisk Invest 3 A/S

Opinion

In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2018, and of the results of the Company's operations for the financial year 1 January - 31 December 2018 in accordance with the Danish Financial Statements Act.

We have audited the Financial Statements of Novo Nordisk Invest 3 A/S for the financial year 1 January - 31 December 2018, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies ("financial statements").

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Statement on Management's Review

Management is responsible for Management's Review.

Our opinion on the Financial Statements does not cover Management's Review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Statements, our responsibility is to read Management's Review and, in doing so, consider whether Management's Review is materially inconsistent with the Financial Statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether Management's Review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, in our view, Management's Review is in accordance with the Financial Statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement in Management's Review.

Management's Responsibilities for the Financial Statements

Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the Financial Statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Novo Nordisk Invest 3 A/S
Independent Auditor's report

- Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the Financial Statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the Financial Statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Hellerup, 14 May 2019

PricewaterhouseCoopers

Statsautoriseret Revisionspartnerselskab
CVR No 33 77 12 31



Mads Melgaard
State Authorised Public Accountant
mne34354



Elife Savas
State Authorised Public Accountant
mne34453

Novo Nordisk Invest 3 A/S
Company information

Company Novo Nordisk Invest 3 A/S
c/o Novo Nordisk A/S
Novo Allé
2880 Bagsværd
Denmark

CVR.no.: 33 76 12 01
Founded: 14 June 2011
Municipality of domicile: Gladsaxe
Financial year: 1 January – 31 December

Board of Directors Karsten Munk Knudsen, chairman
Lene Bang
Tomas Haagen

Executive Management Peter Bøggild

Auditors PricewaterhouseCoopers
Statsautoriseret Revisionspartnerselskab
Strandvejen 44
2900 Hellerup
Denmark

General meeting The Annual General Meeting will be held on 14 May 2019 at the company's address.

Novo Nordisk Invest 3 A/S

Management Review

Main activities

The company's main activity is handling of milestone payments related to intellectual property rights as well as holding of equity investments in companies, and other investments, as well as financial activities, and – at the discretion of the Board of Directors – supporting the operations of such companies.

Development during the financial year

Net profit for Novo Nordisk Invest 3 A/S ended at DKK 730 thousand for the year 2018 compared with net loss of DKK 2,394 thousand for the year 2017.

Events after the balance sheet date

No events have occurred after the end of the reporting period that materially affect the financial position of the company.

Novo Nordisk Invest 3 A/S
Income statement

	Note	2018 DKK '000	2017 DKK '000
Administrative costs		25	20
Other operating income/(expense)	1	-	-
Operating profit/(loss)		(25)	(20)
Financial income	2	990	145
Financial expenses	3	49	2,608
Profit/(loss) before income taxes		916	(2,483)
Income taxes		186	(89)
NET PROFIT/(LOSS) FOR THE YEAR	4	730	(2,394)

For proposed appropriation of net profit see note 4.

Novo Nordisk Invest 3 A/S
Balance sheet at 31 December

	Note	2018 DKK '000	2017 DKK '000
ASSETS			
Other financial assets		81	132
Deferred tax		6,205	-
TOTAL NON-CURRENT ASSETS		6,286	132
Tax receivables		-	7,829
Amounts owed by affiliated companies		414	63,813
Other receivables		-	92
Cash at bank		16,453	16,804
TOTAL CURRENT ASSETS		16,867	88,538
TOTAL ASSETS		23,153	88,670
EQUITY AND LIABILITIES			
Share capital	5	500	500
Retained earnings		2,896	2,166
TOTAL EQUITY		3,396	2,666
Deferred tax liability		-	7,266
TOTAL NON-CURRENT LIABILITIES		-	7,266
Tax payable		19,733	-
Other liabilities		24	78,738
TOTAL CURRENT LIABILITIES		19,757	78,738
TOTAL LIABILITIES		19,757	86,004
TOTAL EQUITY AND LIABILITIES		23,153	88,670

Statement of changes in equity at 31 December

	Share capital DKK '000	Retained earnings DKK '000	Proposed dividends DKK '000	Total DKK '000
2018				
Balance at the beginning of the year	500	2,166	-	2,666
Net profit/(loss) for the year		730		730
Balance at the end of the year	500	2,896	-	3,396

2017

Balance at the beginning of the year	500	4,560	20,000	25,060
Net profit/(loss) for the year		(2,394)		(2,394)
Dividends paid			(20,000)	(20,000)
Balance at the end of the year	500	2,166	-	2,666

Novo Nordisk Invest 3 A/S

Accounting policies

Accounting basis

The Annual Report of the company is prepared in accordance with the Danish Financial Statements Act for a class B enterprise as well as selected rules applying to reporting class C.

The accounting policies applied remain unchanged from last year.

The Annual Report is presented in DKK 1,000.

Translation of foreign currencies

Assets and debt in foreign currencies are translated into Danish kroner at the exchange rates at the balance sheet date. Financial statements of foreign subsidiaries are translated into Danish kroner at the exchange rates at the balance sheet date for the balance sheet items and at average exchange rates for income statement items.

All exchange rate adjustments are recognised in the income statement except exchange rate adjustments arising from:

- translation of subsidiaries' net assets at the beginning of the year at the exchange rates at the balance sheet date
- translation of subsidiaries' income statements at average exchange rates and translation of their balance sheet items at the exchange rates at the balance sheet date
- translation of non-current intra-Group receivables that are considered a supplement to the net assets of the subsidiaries.

The above currency translation differences are recognised directly in equity.

Administrative expenses

Administrative expenses comprise expenses for the management and administration of the company.

According to the Danish Financial Statements Act §98b (3) executive management remuneration is not disclosed.

Financial items

Financial income and expenses include interest income and expenses, realised and unrealised capital gains and losses on securities, debt and transactions in foreign currencies, amortisation of financial assets and liabilities. Financial income and expenses are recognised by the amounts pertaining to the financial year.

Other financial assets

Shares in Novo Nordisk affiliated companies are recognised at fair value.

Amounts owed by affiliated companies

Receivables are stated at amortised cost less write-downs for potential losses on doubtful debts. The write-downs are based on an individual assessment of each debtor.

Tax

The company is jointly taxed with the Danish companies in the Novo Holdings A/S Group. The tax effect of the joint taxation with the parent company and other subsidiaries is allocated to the companies in proportion to their taxable incomes (full allocation). The current tax in the joint taxation is paid by the ultimate parent company, Novo Holdings A/S, which functions as the tax administration company. The jointly taxed Danish enterprises have adopted the on-account taxation scheme.

Short-term debt

Short-term debt are measured at amortised cost.

Dividends

Proposed dividends (not yet declared) for the accounting period are recognised in the equity as proposed dividends.

Novo Nordisk Invest 3 A/S
Notes

	2018	2017
	DKK '000	DKK '000
1 - Other operating income/(expense)		
Other operating income	163,349	161,889
Other operating expense	163,349	161,889
Other operating income/(expense)	-	-

Other operating expense is milestone payments related to the purchase of intellectual property rights in 2015. Novo Nordisk A/S acquired the rights from Novo Nordisk Invest 3 A/S, also in 2015, and Other operating income is payment from Novo Nordisk A/S to cover the milestone payment in accordance with a written agreement between Novo Nordisk A/S and Novo Nordisk Invest 3 A/S. No further payments is expected to take place.

2 - Financial income

Value adjustment of other financial assets	33	145
Foreign exchange rate gain (net)	955	-
Other financial income	2	-
Total financial income	990	145

3 - Financial expenses

Foreign exchange rate loss (net)	-	2,087
Other financial expenses	49	521
Total financial expenses	49	2,608

4 -Proposed appropriation of net profit

Retained earnings	730	(2,394)
Distribution of net profit/(loss)	730	(2,394)

5 - Share capital

The share capital consists of 5,001 shares of nominal value DKK 100. No shares carry any special rights.

	2018	2017	2016	2015	2014
	DKK	DKK	DKK	DKK	DKK
Share capital 1 January	500,100	500,100	500,100	500,000	500,000
Capital contribution	-	-	-	100	-
Balance at the end of the year	500,100	500,100	500,100	500,100	500,000

6 - Contingencies

The company is jointly taxed with the Danish companies in the Novo Holdings A/S Group. The joint taxation also covers withholding taxes in the form of dividend tax, royalty tax and interest tax. The Danish companies are jointly and individually liable for the joint taxation. Any subsequent adjustments to income taxes and withholding taxes may lead to a larger liability. The tax for the individual companies is allocated in full on the basis of the expected taxable income.

The company has no other contingent liabilities.

Notes

7 - Related parties and ownership

Controlling interests

Novo Nordisk A/S, Novo Allé, 2880 Bagsværd, Denmark

Novo Holdings A/S, Tuborg Havnevej 19, 2900 Hellerup, Denmark

Novo Nordisk Foundation, Tuborg Havnevej 19, 2900 Hellerup, Denmark

Basis

Principal shareholder

Controls Novo Nordisk A/S

Ultimate parent of the Group